384 related articles for article (PubMed ID: 17134770)
21. [Value of trimetazidine in the long-term treatment of cardiomyopathies of ischemic origin].
Brottier L; Barat JL; Combe C; Boussens B; Bonnet J; Bricaud H
Ann Cardiol Angeiol (Paris); 1989 Mar; 38(3):179-82. PubMed ID: 2735733
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness and tolerability of bisoprolol vs. nifedipine in uremic patients with ischemic cardiopathy in dialysis treatment].
Cice G; Di Benedetto A; Tagliamonte E; Ferrara L; Sorice P; Iacono A
Cardiologia; 1997 Apr; 42(4):397-403. PubMed ID: 9244644
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study.
Vitale C; Spoletini I; Malorni W; Perrone-Filardi P; Volterrani M; Rosano GM
Int J Cardiol; 2013 Sep; 168(2):1078-81. PubMed ID: 23200272
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
Petelina TI; Gapon LI; Bakhmatova IuA; Zhevagina IA
Ter Arkh; 2005; 77(8):19-23. PubMed ID: 16206600
[TBL] [Abstract][Full Text] [Related]
25. Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia.
Rosano GM; Gebara O; Sheiban I; Silvestri A; Wajngarten M; Vitale C; Aldrighi JM; Ramires AF; Fini M; Mercuro G
Int J Cardiol; 2007 Mar; 116(1):34-9. PubMed ID: 16814412
[TBL] [Abstract][Full Text] [Related]
26. [Incremental doses of diltiazem in patients with coronary artery disease in end-stage renal failure maintained on hemodialysis: which is the optimal dose?].
Cice G; Ferrara L; Tagliamonte E; Di Benedetto A; Iacono A
Cardiologia; 1998 Dec; 43(12):1337-43. PubMed ID: 9988942
[TBL] [Abstract][Full Text] [Related]
27. Enhanced glucose oxidation in exercise-induced myocardial ischemia.
Montague T; DeAlmeida J; Lopaschuk G; Witkowski F; Walker D; Ackman M; Humen D; Dzavik V; Teo K
Can J Cardiol; 1994 Nov; 10(9):913-9. PubMed ID: 7954027
[TBL] [Abstract][Full Text] [Related]
28. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus.
Gazzaruso C; Solerte SB; De Amici E; Mancini M; Pujia A; Fratino P; Giustina A; Garzaniti A
Am J Cardiol; 2006 Jan; 97(2):236-9. PubMed ID: 16442369
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial changes induced by trimetazidine in the myocardium.
Morillas Blasco PJ; Hernándiz Martinez A; Azorín Villena I; Portolés Sanz M; Pallarés Carratala V; Martinez VB; Capdevilla Carbonell C; Aguilar Llopis A; Cosín Aguilar J
Med Sci Monit; 2005 Jun; 11(6):BR162-167. PubMed ID: 15917710
[TBL] [Abstract][Full Text] [Related]
30. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
[TBL] [Abstract][Full Text] [Related]
31. Role of diltiazem in the treatment of silent myocardial ischemia.
Waters D; Juneau M; Baird M; Klinke P; Warnica W; Chin C; Théroux P
J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S15-20. PubMed ID: 1725537
[TBL] [Abstract][Full Text] [Related]
32. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
Tuunanen H; Engblom E; Naum A; Någren K; Scheinin M; Hesse B; Juhani Airaksinen KE; Nuutila P; Iozzo P; Ukkonen H; Opie LH; Knuuti J
Circulation; 2008 Sep; 118(12):1250-8. PubMed ID: 18765391
[TBL] [Abstract][Full Text] [Related]
33. Contributions of myocardial ischemia and heart rate to ST segment changes in patients with or without coronary artery disease.
Häggmark S; Haney MF; Johansson G; Reiz S; Näslund U
Acta Anaesthesiol Scand; 2008 Feb; 52(2):219-28. PubMed ID: 17999710
[TBL] [Abstract][Full Text] [Related]
34. Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease.
Najjar SS; Bottomley PA; Schulman SP; Waldron MM; Steffen RP; Gerstenblith G; Weiss RG
J Cardiovasc Magn Reson; 2005; 7(4):657-66. PubMed ID: 16136855
[TBL] [Abstract][Full Text] [Related]
35. Homocysteine concentrations in type 2 diabetic patients with silent myocardial ischemia: a predictive marker.
Tarkun I; Cetinarslan B; Cantürk Z; Tarkun P; Agaçdiken A; Komsuoglu B
J Diabetes Complications; 2004; 18(3):165-8. PubMed ID: 15145328
[TBL] [Abstract][Full Text] [Related]
36. [Clinical outcomes of trimetazidine in patients with acute ST segment elevation myocardial infarction without ST segment resolution after primary percutaneous coronary intervention].
Peng JJ; Ma ZM; Ren WL; Ren LH; Lei LC; Liang Y
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1399-401. PubMed ID: 19671333
[TBL] [Abstract][Full Text] [Related]
37. [Usefulness of trimetazidine in ischemia-reperfusion lesion. Experimental study in myocardial stunning model].
Morillas P; Hernández A; Pallarés V; Bertomeu V; Roldán FJ; Capdevilla C; Azorín I; Aguilar A; Portolés M; Cosín J
Arch Cardiol Mex; 2004; 74(4):262-70. PubMed ID: 15709502
[TBL] [Abstract][Full Text] [Related]
38. Effects of metabolic approach in diabetic patients with coronary artery disease.
Fragasso G; Salerno A; Spoladore R; Cera M; Montanaro C; Margonato A
Curr Pharm Des; 2009; 15(8):857-62. PubMed ID: 19275650
[TBL] [Abstract][Full Text] [Related]
39. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect.
Belardinelli R; Solenghi M; Volpe L; Purcaro A
Eur Heart J; 2007 May; 28(9):1102-8. PubMed ID: 17456483
[TBL] [Abstract][Full Text] [Related]
40. [Silent myocardial ischemia in hypertensive patients].
Un S; Mengden T; Glänzer K; Vetter H
Praxis (Bern 1994); 2000 Apr; 89(18):757-64. PubMed ID: 10823014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
